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Abstract
Objectives—This study addresses methodological and theoretical questions about the 
association between affect and physical health. Specifically, we examine the role of affect 
variability and its interaction with mean levels of affect to predict antibody (Ab) levels in response 
to an influenza vaccination.
Methods—Participants (N = 83) received the vaccination and completed daily diary measures of 
affect four times a day for 13 days. At one and four months post-vaccination, blood was collected 
from the participants to assess Ab levels.
Results—Findings indicate that affect variability and its interaction with mean levels of affect 
predict an individual’s immune response. Those high in mean positive affect (PA) who had more 
PA variability were more likely to have a lower Ab response in comparison to those who had high 
mean PA and less PA variability. Although it did not interact with mean negative affect (NA), NA 
variability on its own was associated with Ab response, whereby those with less NA variability 
mounted a more robust immune response.
Conclusion—Affect variability is related to immune response to an influenza vaccination and, in 
some cases, interacts with mean levels of affect. These oscillations in affective experiences are 
critical to consider in order to unpack the intricacies of how affect influences health. These 
findings suggest that future researchers should consider the important role of affect variability on 
physical health-relevant outcomes as well as examine the moderating effect of mean affect levels.
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Introduction
Positive affect (PA), such as feelings of joy or happiness, has been repeatedly tied to better 
health and physiological function [1–3], while the converse is true of negative affect (NA; 
e.g., feelings of sadness or anger; [4]). The majority of this research has evaluated affect in a 
singular fashion: by assessing mean or average levels of affect. This ignores the interesting 
possibility that naturally occurring changes in affect over time, uncaptured by averages, 
might also have biological relevance [5].
Fluctuations in the experience of affect over time are referred to as affect variability. This 
construct captures the idea that an individual who varies between extreme highs and lows on 
NA, for example, is starkly different from an individual with consistently moderate levels of 
NA. These two individuals could have the same mean level of NA, however, and would 
therefore be considered equal in many past studies about state affect and physical health (see 
Figure 1). Without consideration of variability, invaluable information about nuances in 
affect is lost. Critically, with knowledge of the interplay between transient affect and 
alterations in physiology (e.g., heart rate, blood pressure, immune function; [6, 7]), it seems 
plausible that these variability differences may have physical health-relevant consequences.
A substantial body of evidence suggests that affect variability may be associated with worse 
mental health (see meta analytic review [8]). For example, Gruber and colleagues [9] found 
that greater PA variability was associated with lower life satisfaction, worse psychosocial 
functioning, and greater depression and anxiety. These findings held even when controlling 
for mean affect, indicating that variability may predict mental health over and above mean 
levels of affect. In the same paper, retrospectively captured affect variability in a separate 
large sample showed that greater PA variability was associated with lower life satisfaction 
and subjective happiness. Similar to these findings, Hardy and Segerstrom [10] found that 
middle-aged participants with greater variability in both PA and NA experienced greater 
psychological distress even when controlling for each respective mean level of affect. These 
findings indicate that greater affect variability is detrimental to mental health.
While this evidence provides convincing support that affect variability has implications for 
psychological health, there is a near absence of work examining how affect variability may 
impact physical health-relevant outcomes. Indeed, variability in other psychological 
characteristics (e.g., life satisfaction, perceived control) is associated with a variety of 
physical health outcomes such as higher mortality risk and worse physical health, and 
physical healthrelevant factors such as lower social support [11–13]. There is also the 
possibility that variability in affect has a physiologically taxing effect on the body. For 
example, given the known cardiovascular, immune, and hormonal alterations with even 
subtle affect change (e.g., [14–17]), variability may take additional energy due to repeated 
physical adjustments. Alternatively, one could argue that variability is healthful given that it 
gives activated physiological systems a break, which prevents biological exhaustion and 
wear and tear on these systems (e.g., [18, 19]). Although these predictions suggest affect 
variability may be tied to physical health, a surprising aspect of the current variability 
literature is the lack of inclusion of objective health-relevant biomarkers. To our knowledge, 
only one study has examined the association between affect variability and a health-relevant 
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biomarker, finding that moderate levels of PA variability were related to daily cortisol 
profiles that are reflective of better physiological functioning [20]. If we are to better 
understand the toll affect variability takes on physical health, we must continue to study 
objective markers of health.
One health-relevant biomarker that may be important in regard to affect variability is 
antibody (Ab) response to a vaccination, such as the influenza vaccine. Ab response, 
typically assessed via blood samples, is often used to study how psychosocial factors impact 
in vivo immune function [21–23]. Given the importance of a quick and large rise in Ab to 
ensure protection against virus exposure [22], vaccination response provides us with a 
health-relevant indicator of immune functioning. For the influenza vaccine, Ab increases one 
month post-vaccination represent the maximum response, while Ab levels after that time 
represent the extent to which the Ab increase is sustained versus declined (e.g., [24]). 
Critically, affect variability experienced immediately following vaccination might have 
physiological implications that may be associated with these Ab levels.
In addition to the limitation of the lack of health-relevant biomarkers, previous affect 
variability and health research has also not included interaction terms between affect 
variability and mean levels of affect. This may be important because variability may have 
different implications based on mean levels [25]. For example, an individual with high mean 
PA may benefit from low variability because he or she would experience consistently high 
levels of PA. On the other hand, an individual low on mean PA may benefit from high 
variability because he or she could at least experience some instances of high PA, which 
could provide temporary benefits. However, this also means that he or she will be 
experiencing instances of extremely low PA when he or she drops far below his or her 
already low PA level. For NA, similar instances could occur. Individuals with high mean NA 
may benefit from high variability because this provides “breaks” in NA (when they drop 
below their usually high NA levels), while those low in mean NA may benefit from low 
variability so that they stay consistently low on NA. As noted by these examples, the 
combination of these potential interaction effects may have profound effects on how affect 
influences health. Although affect papers have not tested this interaction, one study 
investigated the interaction between variability and mean levels of life satisfaction (which is 
only moderately correlated with affect [26]) and showed that greater variability was 
associated with an increase in mortality risk, especially for those with low mean life 
satisfaction [11].
The goal of the present study is to examine how affect variability is associated with Ab 
response to an influenza vaccination. This study fills important gaps in the literature by 
employing a fine-grained methodology to assess affective experiences, measuring a novel 
healthrelevant biomarker that provides rich information about immunocompetence, and 
examining previously unexplored interaction effects. Affect variability was measured using 
the common standard deviation approach (similar to the methods used by the papers 
reviewed above). This method is advantageous in that it represents affect variability with a 
single value that is widely used and understood [27–29]. We interacted mean affect with 
affect variability to uncover whether affect variability has different implications for physical 
health at different levels of mean affect.
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Method
Participants
Participants included 83 undergraduate students (Mage = 18.29; SDage = 0.90; 44% male). 
Sixty-six percent were Caucasian, 24% were Asian, and 10% were other or mixed ethnicity. 
Participants were eligible for participation if they were healthy (i.e., no chronic or acute 
illnesses), were not on a regular medication regimen (with the exception of birth control), 
had never been vaccinated for influenza, and were not pregnant or breastfeeding. 
Participants were compensated $120. All study procedures were approved by the university 
Institutional Review Board.
Procedures
Participants were run in two cohorts across the fall in consecutive years. Participation in the 
study lasted for four months. Participants first completed baseline measures and then 
completed daily diaries four times a day for 13 consecutive days. Data were collected on a 
handheld computer which alerted participants to complete questionnaires one hour after their 
wake time and then three, eight, and 10 hours later. On day three, participants received the 
flu vaccination at a university flu clinic. Before receiving the vaccination, blood was 
collected to measure Ab levels. At one and four months post-vaccination, blood was again 
collected from the participants to assess Ab levels.
Measures
Daily affect—Affect was assessed with a checklist of 12 adjectives adapted from the State 
Adjective Questionnaire [30, 31]. Participants reported how much each adjective represented 
their current affect at each of the diary entries. NA was assessed with the items jittery, 
nervous, unhappy, and sad. PA was assessed with the items active, intense, enthusiastic, 
lively, happy, cheerful, relaxed, and calm. NA and PA items were rated on a scale from 0 
(Not at all) to 4 (Extremely). Cronbach’s alphas for NA ranged from .56 to .84 and 
Cronbach’s alphas for PA ranged from .68 to .85 across the four time points over 13 days.
Affect variability and mean affect—For the purposes of examining how affect 
variability after the vaccination influenced Ab response, only those days on or after the flu 
vaccine (i.e., days 3 through 13) were used to create the affect variability values1. Therefore, 
adjective items were averaged over each of the 44 time points (11 days* 4 assessments) to 
create a NA and PA mean value (split-half reliabilities were 0.91 and 0.90, respectively). 
Then, standard deviations over the 44 time points were calculated for NA and PA (split-half 
reliabilities were 0.67 and 0.68, respectively; reliability estimates reflect similar ones 
reported in previous affect variability literature [32, 33]). These calculations resulted in the 
following variables used for analyses: NA mean (NAMEAN), PA mean (PAMEAN), NA 
standard deviation (NASD), and PA standard deviation (PASD).
Antibody response to vaccination—Ab levels were assessed using venipuncture blood 
sampling. A 20-mL sample of blood was collected immediately before the immunization 
1We used only these days because past research has shown that psychological variables are more influential after the vaccine [42].
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occurred (i.e., baseline) and at one and four month follow-up appointments. The Fluzone 
vaccine consisted of three antigens: A/New Caledonia, A/Panama, and B/Yamanashi or B/
Victoria (B/Victoria was substituted for B/Yamanashi in the second year of data collection). 
Because previous literature has found psychological associations with changes in Ab levels 
with A viruses [21] and past work with this data set has found associations with only the 
A/New Caledonia virus [34], for the purposes of this study, only the A/New Caledonia virus 
was considered.
Ab titers were quantified using a standard hemagglutination inhibition protocol. To quantify 
the volume of a participant’s Ab level, his or her serum was diluted with various saline 
concentrations and then added to a red blood cell culture that contained influenza. The titer 
is the reciprocal of the highest dilution at which a person’s serum continues to prevent red 
cells from clumping. Thus, higher titer values indicate greater volumes of antibodies to the 
vaccine component. All samples were run in duplicate as well as a nonantigen control, and 
all time points for each participant were run in the same assay contemporaneously. The 
antigen used to check Ab levels for the A/New Caledonia virus was A/New Caledonia/20/99 
with a hemagglutination titer of 1024 used at four hemagglutinating units (HAU)/25 μL. The 
A/New Caledonia was obtained from the World Health Organization collaborating center.
Statistical Analysis
The dependent variable in all analyses was Ab level at either one or four months post-
vaccination. The independent variables of interest were NASD and PASD and their 
interactions with NAMEAN and PAMEAN, respectively. NAMEAN, PAMEAN, NASD, and PASD 
were all centered to allow for ease of their interpretations in interaction terms. An interaction 
term between NASD and NAMEAN allowed for a test of whether different values of 
variability in NA had differential implications for Ab response at different levels of mean 
NA. The same was true for the interaction between PASD and PAMEAN. Additionally, before 
interaction terms were added into the model, models with only the main effects were tested.
Ordinary least squares regression models [35] were used to investigate the effect of the 
independent variables on Ab level at one and four months post-vaccination. Due to problems 
of non-constant error variance that was likely due to substantial negative skewness of the 
outcome variable that could not be alleviated using transformations, robust standard errors 
were used in all ordinary least squares regression models. Individuals who started with 
baseline levels at maximum level (N = 5) were excluded from the analyses, as this would not 
allow us to see a change in Ab level.
Consistent with previous research (e.g., [34]), standard control variables were included in 
analyses: baseline Ab level (i.e., immediately before the vaccination occurred), study cohort, 
sex, and ethnicity (Caucasian = 1; other = 0).
A power analysis revealed that for a linear regression with 7 predictors (e.g., NASD, 
NAMEAN, NASD*NAMEAN, baseline Ab level, female, Caucasian, and cohort), 80 
participants would be required to detect a medium to large effect size with 80% power and 
an alpha error probability of 0.05 [36].
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Results
Descriptive Statistics
NAMEAN and PAMEAN were significantly different in average value (t(82) = 8.40, p < .001, 
95% CI of the difference [0.54, 0.88]), while NASD and PASD averages were closer in value 
but still significantly different (t(82) = 2.33, p = .011, 95% CI of the difference [0.01, 0.08]; 
see Table 1). NAMEAN and PAMEAN were negatively correlated (r = −0.31, p = .004), but 
NASD and PASD were positively correlated (r = 0.50, p < .001; see Table 1). In other words, 
those with greater NA variability also experienced greater PA variability. Although NAMEAN 
was positively correlated with NASD (r = 0.63, p < .001), PAMEAN was not correlated with 
PASD (r = 0.16, p = .140).
Affect Variability and Antibody Response
NASD was a predictor of Ab level at one and four months post vaccination (see Tables 2 and 
3; one month: b = −574.31, SE = 271.41, p = .038, 95% CI [−1,115.35, −33.27]; four 
months: b = −692.48, SE = 274.86, p = .014, 95% CI [−1,240.54, −144.42]) when placed in 
a model not controlling for NAMEAN. This indicated that individuals who were lower in NA 
variability were more likely to exhibit higher levels of Ab post-vaccination. However, after 
controlling for NAMEAN, NASD was not significantly associated with Ab level at one month 
(see Table 2; b = −485.84, SE = 341.59, p = .159, 95% CI [−1,166.96, 195.28]) and 
marginally associated with Ab level at four months post-vaccination (see Table 3; b = 
−660.30, SE = 374.67, p = .082, 95% CI [−1,407.55, 86.96]). Additionally, there was no 
significant interaction between NASD and NAMEAN (see Tables 2 and 3; one month: b = 
−201.65, SE = 681.71, p = .768, 95% CI [−1,561.28, 1,157.98]; four months: b = 64.43, SE 
= 696.26, p = .927, 95% CI [−1,324.58, 1,453.44]).
PASD was marginally associated with Ab levels at one and four months post-vaccination (see 
Tables 2 and 3; one month: b = −456.76, SE = 270.85, p = .096, 95% CI [−996.70, 83.18]; 
four months: b = −533.23, SE = 269.33, p = .052, 95% CI [−1,070.26, 3.79]). When 
controlling for PAMEAN, this association became non-significant at one month (see Table 2; 
b = −422.03, SE = 265.01, p = .116, 95% CI [−950.45, 106.39]) and stayed marginally 
significant at four months post vaccination (see Table 3; b = −515.75, SE = 267.27, p = .058, 
95% CI [−1,048.80, 17.30]). However, PASD did significantly interact with PAMEAN to 
predict Ab levels at both time points (see Tables 2 and 3; one month: b = −2,070.98, SE = 
604.88, p = .001, 95% CI [−3,277.37, −864.59]; four months: b = −1,653.02, SE = 508.10, p 
= .002, 95% CI [−2,666.66, −639.38]). Specifically, at high PAMEAN, individuals with 
higher levels of PASD (i.e., more variability) were more likely to have lower Ab levels at 
follow-up (see Figures 2 and 3). This is evidenced by the negative slope of PASD at high 
PAMEAN (one month: dy/dx = −1,510.03, SE = 339.70, p < .001, 95% CI [−2,187.54, 
−832.52]; four months: dy/dx = −1,379.26, SE = 270.44, p < .001, 95% CI [−1,918.77, 
−839.75]). In contrast, when examining the simple effects of the slope of PASD at low 
PAMEAN, the slope was not significantly different from zero (one month: dy/dx = 602.36, SE 
= 421.98, p = .158, 95% CI [−239.26, 1,443.99]; four months: dy/dx = 306.82, SE = 413.56, 
p = .461, 95% CI [−518.20, 1,131.84]), indicating that PASD had no effect on Ab levels for 
individuals with lower PAMEAN.
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Interestingly, when the NA and PA variables were placed in the same model, the findings for 
the interaction between PASD and PAMEAN (see Tables 2 and 3; one month: b = −2,255.78, 
SE = 654.36, p = .001, 95% CI [−3,561.88, −949.67]; four months: b = −1,882.19, SE = 
643.69, p = .005, 95% CI [−3,167.36, −597.01]) as well as the main effect of NASD (see 
Tables 2 and 3; one month: b = −762.24, SE = 383.19, p = .051, 95% CI [−1,527.09, 2.62]; 
four months: b = −909.15, SE = 448.09, p = .047, 95% CI [−1,803.80, −14.51] held2.
Discussion
Our findings indicate that affect variability, and the interaction between that variability and 
mean levels of affect, significantly influence immunocompetence in response to the flu 
vaccination. NA variability, along with the interaction between PAMEAN and PA variability, 
predicted Ab levels following a vaccination, and these findings held when they were all 
placed in the same model (i.e., model 9 in Tables 2 and 3). These results suggest that affect 
variability may have important implications for physical health, especially in the context of 
the immune system.
The results regarding PA are nuanced and depend on the interaction between PA mean and 
variability. Individuals high in PAMEAN who had low variability (consistently stayed at their 
high PA level as opposed to drastically bouncing up and down around it) had a robust 
immune response. However, if an individual had a high PAMEAN, high PA variability was 
detrimental for mounting a large Ab response. It is possible that for an individual with high 
PA variability, the negative ramifications of dropping far below a mean level are not offset 
by the peaks of being above a mean level. In contrast, for individuals with low levels of 
PAMEAN, variability in PA had no effects on Ab levels (see Figures 2 and 3). These PA 
findings are consistent with some of the current affect variability and physiological findings 
(e.g., [20] Study 1).
High NA variability was associated with lower Ab levels (see model 1 in Tables 2 and 3). 
However, when interpreting the meaning of these results, it is important to consider the 
connection between mean levels and variability. Standard deviations can be confounded with 
mean levels (e.g., [37]), and indeed, NAMEAN and NASD were highly correlated in this study 
(see Table 1). Therefore, it was important to control for NAMEAN when determining the 
effect of NASD on Ab levels. When controlling for NAMEAN, the main effect of NASD 
became nonsignificant at one month and marginal at four months post vaccination. This 
could imply that NAMEAN was an important factor driving the association between NASD 
and Ab levels. However, the coefficient of NASD did not dramatically reduce from model 1 
without the mean level control (one month: −574.31; four months: −692.48) to model 3 with 
the mean level control (one month: −485.84; four months: −660.30), suggesting that maybe 
with more participants, this effect would have remained significant. Nevertheless, given the 
high correlation between mean level and standard deviation, we tested our models with the 
2Past studies have looked at other variables including loneliness, social network, and stress related to vaccine response (including 
studies that have used this data set). When considering these psychosocial variables, the pattern of results, especially the interaction 
terms of interest, was unaffected. The only exceptions to this were that PASD became significant as a main effect and NASD became 
non-significant in some models. This non-significance may reflect the substantial overlap in NASD with loneliness (r = 0.47, p < .001) 
and stress (r = 0.52, p < .001).
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alternative variability indicator of the mean square successive differences (MSSD). We 
found no main effect of NAMSSD in any of the models. Interestingly, NAMEAN and NAMSSD 
were not significantly correlated (r = 0.16, p = 0.16), in contrast to the high correlation 
between NAMEAN and NASD (r = 0.63, p < .001). This may suggest that even when NA 
variability is not confounded with mean levels, NA variability has little effect on biomarkers 
(at least in healthy college samples). With regard to PA, PAMEAN and PASD were not 
confounded (see Table 1), which may explain why there were interactive effects of PAMEAN 
and PASD on Ab levels. It is interesting that NA variability is related to NAMEAN levels 
while PA variability is not related to PAMEAN levels. Indeed, many studies only find effects 
with PA variability as opposed to NA variability (e.g., [9,20]), providing evidence that these 
two valence types should be examined as separate variables as opposed to combining them 
into one variability variable.
Why is affect variability associated with Ab levels? One explanation may be connected to 
the influence of affect variability on affective processes. High affect variability may be 
indicative of poor affect regulation, which has implications for health [38, 39]. Additionally, 
affect variability is a key factor in neuroticism (e.g., [40]), and high levels of neuroticism 
have been shown to negatively influence immune response [41]. Alternatively, affect 
variability might be related to health through its influence on health behaviors. For example, 
it is possible that affect variability impacts sleep, eating behaviors, and/or the use of alcohol 
and tobacco (all of which have been shown to affect immunity [22, 42]). Yet another 
explanation could be that affect variability may alter the concentration of circulating stress-
related hormones (e.g., cortisol, epinephrine, norepinephrine), which can bind to and alter 
the function of immune cells involved in the Ab response [43]. These possible pathways are 
likely interrelated and may all contribute in some way to how affect variability gets “under 
the skin” to influence Ab responses to vaccines. Thus, future research should consider these 
potential pathways in the affect variability and Ab response relationship to determine how 
affect variability influences immune responses.
This study has several potential limitations. First, although we used a common metric of 
affect variability, namely, the standard deviation approach, there are also other methods (e.g., 
insufficient variations, adjusted squared successive difference scores, core affect variability; 
[40, 44–47]) that were not considered. However, we chose the standard deviation approach 
since it is easy to understand and the most commonly used technique, in addition to the fact 
that different variability measures often lead to similar results (e.g., [9, 46], our results 
reported above with MSSD). A second limitation was that we did not include the effect of 
affect variability before the vaccination. Because past research has shown that psychological 
variables are more influential after the vaccine [42], we used only the days on or after the flu 
vaccination to calculate variability3. Third, we only considered one virus. This decision was 
based on previous findings that psychosocial variables influence responses to only some 
virus strains [24, 41]. Although it is difficult to say whether certain viruses are more 
sensitive to psychosocial factors, it has been suggested that there may be differences in strain 
3Furthermore, we felt that the two days before the vaccination would not provide sufficient data because participants were still new to 
self-reporting and that two days might not be sufficient to capture a large enough sample to reflect variability before the vaccination. 
Therefore, the first two days were considered to be a diary run-in.
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novelty and the participant’s previous exposure to the strain that could explain the differing 
findings in the literature [48].
Fourth, statistical significance does not translate to clinical significance. In our sample, all 
but 5 participants at one month and all but 6 participants at four months post vaccination had 
Ab levels above 40 titers, which is considered the clinically protective level [49, 50]. Similar 
vaccine studies using young adult samples have shown that the majority of the sample are 
protected against the virus after vaccination (e.g., [34, 51]). Nevertheless, there was 
sufficient titer variability within our sample to see statistically significant associations with 
affect variability and mean levels. Additionally, we included pre-vaccine levels as a control 
variable in all analyses (as suggested by [49]). Therefore, our findings still speak to how 
affect variability may influence immune responses to vaccines in young, healthy individuals.
This study emphasizes the importance of assessing the effects of affect variability in addition 
to mean levels of affect on an objective health-relevant biomarker. Mean levels of affect do 
not explain the whole story about how an individual may mount an immune response. 
Previous research may have overlooked important intricacies about the influence of affect 
because variability was not assessed. In our study, if we only considered mean levels of PA 
or NA, then we would have found no influence of affect on Ab response. This would have 
resulted in an incomplete understanding of the effects of affect on vaccination response. The 
results of this study should encourage future researchers to consider affect variability in 
addition to mean levels of affect and point to the possibility that it may have unique effects 
on other physical health-relevant parameters. Assessing vacillations in affect will help paint 
a more vivid picture of how our affective experiences influence physical health.
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Highlights
• Affect variability has important implications for immune response.
• Negative affect variability is related to lower antibody production.
• Positive affect variability and mean levels interact to influence antibody 
production.
• Future researchers should consider how affect variability influences health.
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Figure 1. 
Two individuals with the same mean level of negative affect but different negative affect 
variability.
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Figure 2. 
PASD and PAMEAN interaction on antibody (Ab) titers at one month post-vaccination. Low 
PAMEAN is one SD below the mean on PAMEAN while high PAMEAN is one SD above the 
mean on PAMEAN. Lines represent adjusted predictions. Shaded regions are the 95% 
confidence intervals around the predictions. Regions of PAMEAN (low vs. high) that do not 
overlap are significantly different from one another in terms of the predicted Ab level. 
Possible predicted values are between 0 and 1024 titers. However, confidence intervals 
exceed this range.
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Figure 3. 
PASD and PAMEAN interaction on antibody (Ab) titers at four months post-vaccination. Low 
PAMEAN is one SD below the mean on PAMEAN while high PAMEAN is one SD above the 
mean on PAMEAN. Lines represent adjusted predictions. Shaded regions are the 95% 
confidence intervals around the predictions. Regions of PAMEAN (low vs. high) that do not 
overlap are significantly different from one another in terms of the predicted Ab level. 
Possible predicted values are between 0 and 1024 titers. However, confidence intervals 
exceed this range.
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